Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now


You can switch off notifications anytime using browser settings.

Recos

Portfolio

Loading...
Select Portfolio and Asset Combination for Display on Market Band
Select Portfolio
Select Asset Class
Show More
Download ET MARKETS APP

Get ET Markets in your own language

DOWNLOAD THE APP NOW

+91

CHOOSE LANGUAGE

ENG

  • ENG - English
  • HIN - हिन्दी
  • GUJ - ગુજરાતી
  • MAR - मराठी
  • BEN - বাংলা
  • KAN - ಕನ್ನಡ
  • ORI - ଓଡିଆ
  • TEL - తెలుగు
  • TAM - தமிழ்
Drag according to your convenience
ET NOW RADIO
ET NOW
TIMES NOW

Buy Sun Pharmaceutical Industries, target Rs 610: Shrikant Chouhan

ETMarkets.com|
Jan 05, 2018, 08.24 AM IST
0Comments
Shrikant Chouhan of Kotak Securities Limited has a buy call on Sun Pharmaceutical Industries with a target price of Rs 610.

The current market price of Sun Pharmaceutical Industries is Rs 581.

Time period given by the analyst is 'Intra Day' when Sun Pharmaceutical Industries price can reach defined target.

Shrikant Chouhan recommended to keep a stop loss at Rs 565.

Sun Pharmaceutical Industries, incorporated in the year 1993, is a Large Cap company (having a market cap of Rs 1,39,399.87 Crore) operating in Pharmaceuticals and health care sector.

The company's top management includes Mr.Ashwin Dani, Mr.Dilip S Shanghvi, Mr.Hasmukh S Shah, Mr.Israel Makov, Mr.Kalyanasundaram Subramanian, Mr.Keki M Mistry, Mr.S Mohanchand Dadha, Mr.Sailesh T Desai, Mr.Sudhir V Valia, Ms.Rekha Sethi.

Company has Deloitte Haskins & Sells as its auditors.

As on 30-09-2017, the company has a total of 2,399,308,086 shares outstanding.
0Comments

Also Read

Buy Wipro, target Rs 330: Shrikant Chouhan

Buy NCC, target Rs 140: Shrikant Chouhan

Buy Escorts, target Rs 740: Shrikant Chouhan

Buy Punjab National Bank, target Rs 190: Shrikant Chouhan

Comments
Add Your Comments
Disclaimer: This recommendation is analyst's own and does not represent those of economictimes.com & ETMarkets.com. Please consult your financial advisor before taking any position in the stock/s mentioned.

Loading
Please wait...